AptarGroup, Inc. · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · United States
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-08-22$141.43 RISE2025-12-09$115.72 PEAK2026-02-23$145.72 185d | -18.2% 109d | Missed | Missed | — | — | +25.9% 76d | Missed |
DROP2024-11-29$172.96 RISE2025-04-08$133.66 PEAK2025-07-03$161.04 216d | -22.7% 130d | Missed | Missed | — | — | +20.5% 86d | Missed |
DROP2022-08-16$112.07 RISE2022-10-12$93.37 PEAK2023-01-06$114.06 143d | -16.7% 57d | Missed | Missed | — | — | +22.2% 86d | Missed |
DROP2022-02-28$121.88 RISE2022-06-16$94.77 PEAK2022-08-16$112.07 169d | -22.2% 108d | Missed | Missed | — | — | +18.3% 61d | Missed |
DROP2020-01-16$118.22 RISE2020-03-23$83.93 PEAK2020-06-08$113.58 144d | -29.0% 67d | Missed | Missed | — | — | +35.3% 77d | Missed |
CRYSTAL LAKE, Ill., May 27, 2026--Aptar to Participate in Upcoming Investor Conferences
Get this weekly dividend update on Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend dates and pay dates.
AptarGroup (NYSE:ATR) used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results. President and Chief Executive Officer Stephan Tanda told shareholders that he p
AptarGroup (NYSE:ATR) used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results. President and Chief Executive Officer Stephan Tanda told shareholders that he p
2026-05-09. The following slide deck was published by AptarGroup, Inc.
CRYSTAL LAKE, Ill - AptarGroup, Inc. , a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today highlighted how its patented, high performance...
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
May 6, 2026 Annual Meeting of Stockholders Stephan Tanda, President & CEO Irene Hudson, EVP, Chief Legal Officer and Secretary ...
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $144 to $145.
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its quarterly result this time last week. The...
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its quarterly result this time last week. The...
AptarGroup Inc (ATR) reports an 11% sales increase, driven by robust demand in injectables and consumer healthcare, despite margin pressures and segment-specific hurdles.
AptarGroup Inc (ATR) reports an 11% sales increase, driven by robust demand in injectables and consumer healthcare, despite margin pressures and segment-specific hurdles.
AptarGroup (ATR) has drawn fresh attention after reporting first quarter 2026 results that topped consensus forecasts for both earnings and revenue, even though net income and earnings per share were lower than a year earlier. See our latest analysis for AptarGroup. Even with the earnings and revenue beat, AptarGroup’s recent share price performance has been weak, with a 30 day share price return decline of 6.1% and a 1 year total shareholder return decline of 20.9%, pointing to fading...
AptarGroup (ATR) has drawn fresh attention after reporting first quarter 2026 results that topped consensus forecasts for both earnings and revenue, even though net income and earnings per share were lower than a year earlier. See our latest analysis for AptarGroup. Even with the earnings and revenue beat, AptarGroup’s recent share price performance has been weak, with a 30 day share price return decline of 6.1% and a 1 year total shareholder return decline of 20.9%, pointing to fading...
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full analysis here.
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call May 1, 2026 9:00 AM EDTCompany ParticipantsMarry Skafidas - Senior Vice President of Investor Relations &...
AptarGroup (NYSE:ATR) reported first-quarter 2026 results that management said largely tracked expectations, with currency providing a lift to reported growth while underlying performance reflected mixed conditions tied mainly to an expected destocking cycle in emergency medicine. On the call, Pres
AptarGroup (NYSE:ATR) reported first-quarter 2026 results that management said largely tracked expectations, with currency providing a lift to reported growth while underlying performance reflected mixed conditions tied mainly to an expected destocking cycle in emergency medicine. On the call, Pres
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATR | -2.66% | -18.80% | -5.01% | -26.86% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.63% | -13.08% | -1.57% | -39.55% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.78M | $350.91M | 0.01% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 1.03M | $129.57M | 0.01% | Added+2.5% | 2026-03-31 |
| DEShaw | quant | 482.0K | $60.74M | 0.04% | Added+144.5% | 2026-03-31 |
| RenTech | quant | 172.8K | $21.78M | 0.03% | Added+20.3% | 2026-03-31 |
| Citadel | multi-strat | 83.5K | $10.53M | 0.01% | New | 2026-03-31 |
| TwoSigma | quant | 62.5K | $7.88M | 0.01% | Trimmed-68.7% | 2026-03-31 |
| TRowePrice | fundamental | 58.4K | $7.36K | 0.00% | Added+10.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 1.36 | — | — |
| 2026-04-30 | 1.15 | 1.19 | +3.48% |
| 2026-02-05 | 1.23 | 1.25 | +1.74% |
| 2025-10-30 | 1.57 | 1.62 | +3.08% |
| 2025-07-31 | 1.59 | 1.66 | +4.67% |
| 2025-05-01 | 1.16 | 1.20 | +3.90% |
| 2025-02-06 | 1.26 | 1.52 | +20.95% |
| 2024-10-24 | 1.42 | 1.49 | +4.93% |
| 2024-07-25 | 1.35 | 1.37 | +1.48% |
| 2024-04-25 | 1.15 | 1.26 | +9.76% |
| 2024-02-08 | 1.12 | 1.21 | +8.23% |
| 2023-10-25 | 1.27 | 1.39 | +9.45% |
| 2023-07-27 | 1.14 | 1.23 | +8.27% |
| 2023-04-27 | 0.90 | 0.95 | +5.41% |
| 2023-02-16 | 0.79 | 0.92 | +16.38% |
| 2022-10-27 | 0.94 | 0.95 | +1.54% |